Pramand LLC

Pramand LLC develops implantable medical devices using proprietary hydrogel technology to address unmet clinical needs across surgical interventions. The company focuses on creating hydrogel-based solutions that improve patient outcomes while reducing therapy costs. Pramand's portfolio includes three primary product lines: a hydrogel implant for minimizing intrauterine adhesions (IUAs) in gynecological procedures, a dural sealant for watertight dural closure following craniotomy in neurosurgery, and a hemostatic sealant patch for controlling moderate surgical bleeding. The company operates through a business model of self-funding preclinical development with financial partners supporting clinical development and commercialization. Pramand's leadership team has successfully launched over ten hydrogel-based medical device companies that have generated over $4 billion in value and exits, collectively serving over 5 million patients worldwide. The company's proprietary hydrogel platform positions it as a specialized developer in the implantable device sector, with particular expertise in surgical sealants and hemostatic applications.